MEDICAGO
7.12.2020 13:32:51 CET | Business Wire | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today.
Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond to the needs of the global public health community and medical authorities and professionals.
“Taking on this new role with Medicago during this exciting time is a great honour for me,” said Mr. Nagao, President and Chief Executive Officer, Medicago. “I want our employees, investors, and stakeholders such as the Government of Canada to know that I will put all my efforts into seeing our COVID-19 and influenza vaccines through to a successful launch to protect as many people as possible.”
From 2007 to 2017, Mr. Nagao oversaw the establishment of Mitsubishi Tanabe Pharma Corporation’s U.S. presence and led the team that successfully achieved NDA of RADICAVA®, the first FDA-approved drug in over 20 years for the patients with Amyotrophic Lateral Sclerosis (ALS). Prior to that, Mr. Nagao was a Managing Director in investment banking at J.P. Morgan and Deutsche Bank where he was responsible for global clients and leading equity and cross-border M&A transactions in the pharmaceutical and biotechnology sector in North America, Japan and Europe. He has an MBA from Harvard Business School.
Mr. Nagao succeeds Dr. Bruce D. Clark, who held the position of President and CEO of Medicago since 2017 and was instrumental in the development of Medicago’s COVID-19 vaccine candidate.
Medicago recently announced the start of Phase 2/3 clinical trial of its plant-derived VLP vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity, based on the positive Phase 1 results and subsequent allowance to advance to Phase 2/3 by the Canadian regulatory authorities. The company is also building a new facility in Quebec to increase Canada’s domestic capacity for manufacturing vaccines, producing up to a billion doses annually.
“Medicago is at an inflection point. We are moving from a research and development focused organization to become a commercial entity supplying vaccines to Canadians and people around the world,” said Mr. Nagao.
About Medicago
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
For more information: www.medicago.com
To learn more about our plant-based technology: Video / Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ADX and Its Listed Companies Connect with International Capital at Global Investor Roadshow in New York22.9.2026 14:01:00 CEST | Press release
14 ADX-listed companies will present their growth strategies and equity stories to international investors The Abu Dhabi Securities Exchange (ADX) Group is heading to New York for its annual Global Investor Roadshow and Conference, held in collaboration with Morgan Stanley on 24 and 25 September 2026. This is part of ADX’s ongoing commitment and engagement outreach to institutional investors across key global financial centers. The ADX event in New York will highlight the investment opportunities Abu Dhabi’s capital markets offer through its leading listed companies, as the ADX supports Abu Dhabi’s long-term economic vision and sustainable economic growth as a global capital hub. H.E. Ghannam Butti Almazrouei, Chairman of the ADX, and Abdulla Salem Alnuaimi, Group Chief Executive Officer, will lead the delegation. They will be joined by senior management and investor relations officers from 14 ADX-listed companies. Direct discussions with management teams will enable investors to explo
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial22.9.2026 14:00:00 CEST | Press release
– In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline –- In people with AMKD and type 2 diabetes, treatment with inaxaplin led to a reduction in UACR of -17.3% at Week 13 compared to baseline –- Inaxaplin was generally safe and well tolerated in both cohorts –- Vertex has completed enrollment in the AMPLITUDE trial and remains on track for interim analysis results in early 2027, which, if positive could support potential accelerated approval in the US - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes. In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care. Forty-one people were enrolled and dosed in two cohorts: 1) peop
INNIO Receives Credit Rating Upgrades and Reaffirms Financial Policy to Support Profitable Growth22.9.2026 14:00:00 CEST | Press release
INNIO N.V. (Nasdaq: INIO) (“INNIO” or the “Company”) today announced that Fitch Ratings has upgraded the Company’s credit ratings, following a recent upgrade by Moody’s Ratings. INNIO also reaffirmed its financial policy framework, which supports investment in profitable growth while continuing to strengthen the Company’s balance sheet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922051908/en/ INNIO Receives Credit Rating Upgrades and Reaffirms Financial Policy to Support Profitable Growth Credit rating upgrades Moody’s upgraded INNIO’s Corporate Family Rating by one notch to Ba3 from B1 and revised the outlook to positive from stable. Fitch Ratings upgraded INNIO’s Long-Term Issuer Default Rating by two notches to BB from B+, with a stable outlook. Fitch also upgraded INNIO’s senior secured debt rating to BB+ from B+. These upgrades reflect INNIO’s strong operating performance and cash flow generation, supported by fa
Who Decides What’s Safe Online? Trust Issues Returns for Season 222.9.2026 14:00:00 CEST | Press release
WebPurify, an IntouchCX Company specializing in trust and safety, has launched the season 2 of Trust Issues, a podcast exploring the technology, policies, and human decisions shaping the future of online safety. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922209613/en/ WebPurify, an IntouchCX Company specializing in trust and safety, has launched the season 2 of Trust Issues, a podcast exploring the technology, policies, and human decisions shaping the future of online safety. Who ultimately decides what stays up and what comes down in digital spaces? Season 2 answers that question by examining how AI capabilities, shifting market place regulations, human judgement and operational constraints intersect. Moving beyond simple technical solutions, each episode goes behind the scenes of the complex pressures facing digital platforms today, from cost efficiencies to high stake compliance, and the strategies leaders use to b
Manhattan Associates Announces EditionsTM for its Industry-Leading Solutions, Making Them Accessible at Every Stage of Growth22.9.2026 14:00:00 CEST | Press release
New offering gives commercial and growing enterprises the right-sized path to start their journey with Manhattan, and scale on the same platform as their business grows Manhattan Associates (NASDAQ: MANH), the global leader in supply chain commerce with unmatched AI capabilities, today announced the commercial launch of Editions for Manhattan Active® solutions. Editions provide a new way for companies of all sizes and across industries to partner with Manhattan. They are designed to help growing organizations make a durable, long-term technology decision from the start. As complexity increases, customers can unlock additional capabilities on the same platform, rather than starting over. Built for ActiveWarehouse™, ActiveTransportation™, ActiveStore™ and ActiveOrder™, on Manhattan’s award-winning ActivePlatform™, there are three Editions available: Essentials, Enterprise and Enterprise Premier. Regardless of the Edition selected for each solution, companies gain access to the power of a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom